Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Alex Azar, speaking in Uganda, told reporters that he and others are “very concerned” and urged Tanzania’s government to share laboratory results regarding the case. The Ebola outbreak in neighboring Congo has become the second-deadliest in history, with confirmed cases now exceeding 3,000. Azar said efforts were underway to secure Tanzania’s compliance with international health regulations and obligations to the World Health Organization “to protect Tanzanians as well as all people in the region.” Tanzania’s government said Saturday there is no confirmed case of Ebola in the East African nation. No confirmed Ebola case has ever been recorded there. WHO in a statement last week noted a rumor regarding a death in Tanzania from an unknown illness and said it was sending a technical team to investigate “as a matter of urgency.” According to an internal WHO document seen by The Associated Press, the patient, a 34-year-old woman, died on Sept. 8 and was buried that day. It was not clear where she died. The document says the victim most recently was a student in central Uganda, where she visited health facilities on a research mission, before returning to Tanzania on Aug. 22. No case of Ebola has been reported in Uganda’s central region. “This mysterious disease has to be investigated and samples have to be tested. We couldn’t rule out any of the viral hemorrhagic fevers and the investigation will continue,” Dr. Yonas Woldemariam, the WHO representative in Uganda, said Monday. The Ebola outbreak in eastern Congo, which was declared over a year ago, has killed nearly 2,000 people. Health workers have been challenged by community mistrust and insecurity caused by years of rebel attacks. Cases of Ebola patients crossing borders during this outbreak have been rare. In June, a family of Congolese with sick family members crossed into Uganda via a bush path. Two died of Ebola inside Uganda. And in August, a Congolese girl tested positive for Ebola and later died in Uganda after traveling from Congo. ___ Follow Africa news at https://twitter.com/AP_Africa

Output: US urges transparency in Ebola-like death in Tanzania.


Input: Consider Input: Amid a scarcity of doctors and public hospitals, India is relying on its mobile telephone network, the second largest in the world with 950 million connections, to reach places where health workers rarely go. “It’s a huge priority for us,” health ministry official Manoj Jhalani told Reuters, adding that the service, advising on vaccinations and vitamin supplements, will launch in eight of the country’s Hindi-speaking states by Aug. 15.”These are the most cost-effective health interventions,” said Jhalani, the supervisor of the project, named ‘Kilkari,’ or “Baby’s Gurgle”, which will tailor its recorded messages to individual stages of pregnancy or the age of a newborn. Poor sanitary conditions and stark poverty prevail in many villages in India, which recorded 50,000 maternal deaths in 2013, when 1.3 million children died before turning five. Preventable hazards such as pneumonia, or poor nutrition, cause most deaths of mothers and babies. Many women give birth at home without access to clean water and toilets, while public medical clinics remain dilapidated and overcrowded. Over the last 18 months, almost 100,000 rural families have signed up for the voice message project, first piloted by the government of the impoverished, but resource-rich, eastern state of Bihar. With India’s health services starved for funds, the mobile phone messages are a cheaper way to spread basic tips on health. Payment delays have led to months of disruption in the traditional system of home visits by health workers to encourage pregnant women to take medicine and follow safety measures. The new project, backed by the Bill and Melinda Gates Foundation and the charity arm of British broadcaster BBC, will make use of a national database to track pregnant women. Another service, Mobile Academy, will also use recorded messages to help train India’s millions of health workers. Health experts welcome the initiatives, but warn such mobile phone campaigns will not be enough to cut mortality rates unless India ramps up health services, particularly in rural areas. “This (mobile services) will have a very marginal effect,” said Dileep Mavalankar, director of the Indian Institute of Public Health in the western state of Gujarat, adding that the health system needed to be strengthened in remote areas.

Output: India bets on mobiles in battle on maternal, child deaths.


Input: Consider Input: "As the drug reported on is currently not available a precise cost may not yet be known. However – while not providing a precise cost of this treatment, the story indicated that it is likely to cost more than the currently approved and available clopidogrel especially in 2011 when it will be off patent. The story described the benefits of treatment with ticagrelor in terms of the absolute reduction in risk of the composite endpoint of heart attack, stroke, and death from cardiovascular disease as well as the relative risk reduction. The story mentioned the disadvantage that this medication required pills to be taken twice a day (as opposed to the once a day dosing with the currently available medications). It also mentioned that this drug had the potential for resulting in shortness of breath and also that the results of the medication wore off faster than the currently available medication. It could have provided readers with some explanation about why this has the potential to be a problem. Although it included a quote from a doctor indicating that this drug would likely become ""the new standard of care,"" the story did not adequately highlight the new side effects seen with this new treatment to help readers understand that it may not be an appropriate treatment option for all individuals with acute coronary syndrome. Lastly and perhaps most importantly –  the story included the statement ""There was no increase in the risk of dangerous bleeding associated with the new drug."" This statement is misleading as the study reported on found that outside of bleeding related to coronary-artery bypass grafting, ticagrelor was associated with higher rates of major bleeding (4.5% versus 3.8). Nonetheless, overall, the story meets the standard for discussing harms. The story included sufficient information for readers to appreciate that the study involved a large number of patients and it described the main comparison in absolute terms. It could have mentioned that this was a phase III clinical trial designed to examine both the drug’s safety and efficacy. It also could have discussed how the result of the current study differs from the previous large, phase III clinical trials that have been conducted. While mentioning that acute coronary syndrome results in the hospitalization of more than 1.3 million Americans per year, the story did not engage in overt disease mongering. There was only one clinician quoted with respect to the utility of the medication ticagrelor. The story should have included other perspectives. The story mentioned that there were other medications that prevent platelets from forming clumps, mentioning the two prescription medications, clopdogrel and pasugrel by name. The part of the story on the treatment of acute coronary syndrome using the drug ticagrelor ended with a clear sentence indicating that the company is hoping to have FDA approval for this drug by the end of the year and have it commercially available for consumers by early 2010. Placing it here means it could be missed by readers. Further what a company ‘hopes’ may not translate to the drug being available on the timetable outlined. However – a careful read of this story would results in correctly understanding that this drug is currently not FDA approved for sale. The story was about a new medication which is not yet available. does not appear to rely on a press release"


Output: Two new blood thinners better than Plavix and warfarin, studies say